Debora Plehn-Dujowich

Debora Plehn-Dujowich, Ph.D. is an associate in the Intellectual Property Practice Group on the Patents Team.  She focuses her practice on biotechnology and biochemistry.  Debora’s research experience in both Universities and Research Institutes has enriched her knowledge of the importance of protecting both national and international intellectual property rights in an invention.

In General.  Debora received her J.D. from Temple University Beasley School of Law, where she made Dean’s List and worked part-time as a law clerk.  She completed her B.S. in biochemistry at Geneva University in Switzerland, where she was also awarded an M.S. in biochemistry.  Debora obtained her M.S. in life sciences from the Weizmann Institute of Science in Rehovot, Israel, where she focused on award-winning hormone and cancer research, focusing on ovarian cancer.  She earned her Ph.D. in biology at Yale University under the supervision of Professor Sidney Altman, who won the Nobel Prize in chemistry for his research on RNAse P.  Debora conducted research applying novel ribozyme technology to inhibit influenza infection in cells.  She was also a post-doctoral research fellow at the Wistar Institute in Philadelphia, where she worked on confocal microscopy studies of virus-infected cells under a grant from the NIH. Following her post-doctorate, Debora was also an assistant professor of biology and chemistry at Northampton Community College in Bethlehem, Pennsylvania, where she won grants from the NSF and awards for developing new courses such as biology for education majors and history of science.

Debora has several publications in scientific journals, including the Proceedings of the National Academy of Sciences and Nature.
Debora is fluent in English, French and Spanish, and also speaks some German and Hebrew.



From the Blog

Privately Held Medical Device and Drug Companies Face Unique Sunshine Act Challenges

As widely reported, the Centers for Medicare and Medicaid Services (“CMS”) recently issued regulations implementing the Sunshine Act provisions of the Affordable Care Act. ...

What Goes Up…Must Come Down: Viagra patent invalidated by Canadian Supreme Court

Pfizer and Teva have been fighting a legal battle over Pfizer’s patent for Viagra in Canada.  The first shot was fired when Novopharm Limited,...

The Perils and Promise of 3D Printing: Are DIY Life Sciences in Your Future?

With news that 3D printing (without question one of the coolest technologies to come down the road in quite some time) can be used...